Immune checkpoint inhibitors (ICIs) that target cytotoxic T lymphocyte antigen 4 (CTLA-4) or the programmed cell death (ligand) 1 [PD-(L)1] pathway have achieved impressive success in the treatment of different cancer types [1]. This evidence concerns the gene CD274 and cancer.